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Background: AKT is commonly overexpressed in tumours and plays an important 53 
role in the metabolic reprogramming of cancer. We have used magnetic resonance 54 
spectroscopy (MRS) to assess whether inhibition of AKT signalling would result in 55 
metabolic changes that could potentially be used as biomarkers to monitor response to 56 
AKT inhibition.  57 
Methods: Cellular and metabolic effects of the allosteric AKT inhibitor MK-2206 58 
were investigated in HT29 colon and PC3 prostate cancer cells and xenografts using 59 
flow cytometry, immunoblotting, immunohistology and MRS. 60 
Results: In vitro treatment with MK-2206 inhibited AKT signalling and resulted in 61 
time-dependent alterations in glucose, glutamine and phospholipid metabolism. In 62 
vivo, MK-2206 resulted in inhibition of AKT signalling and tumour growth compared 63 
with vehicle-treated controls. In vivo MRS analysis of HT29 subcutaneous xenografts 64 
showed similar metabolic changes to those seen in vitro including decreases in the 65 
tCho/water ratio, tumour bioenergetic metabolites and changes in glutamine and 66 
glutathione metabolism. Similar phosphocholine changes compared to in vitro were 67 
confirmed in the clinically relevant orthotopic PC3 model. 68 
Conclusion: This MRS study suggests that choline metabolites detected in response 69 
to AKT inhibition are time- and microenvironment-dependent, and may have 70 
potential as non-invasive biomarkers for monitoring response to AKT inhibitors in 71 





The AKT/PKB (Protein Kinase B) serine/threonine kinase, with three different 76 
isoforms: AKT1, AKT2 and AKT3, is one of the core components of the PI3K 77 
signalling cascade, regulating cell proliferation, survival and metabolism, and is 78 
frequently activated in cancer (Manning and Toker, 2017). Multiple AKT inhibitors 79 
are now at various stages of clinical development (Brown and Banerji, 2017; Khan et 80 
al, 2013; Nitulescu et al, 2016). AKT inhibitors fall predominantly into two classes: 81 
ATP-competitive inhibitors and allosteric inhibitors of AKT (Brown and Banerji, 82 
2017; Khan et al, 2013; Nitulescu et al, 2016). MK-2206 is a potent oral allosteric 83 
pan-AKT inhibitor with potential anti-neoplastic activity and is currently being 84 
evaluated in numerous clinical trials (Brown and Banerji, 2017; Khan et al, 2013; 85 
Nitulescu et al, 2016). Single-agent trials with this agent have generally shown anti-86 
proliferative, rather than anti-tumour activity, with stable disease identified as the best 87 
overall response (Ahn et al, 2015; Yap et al, 2011; Yap et al, 2014). Therefore, 88 
identification of non-invasive biomarkers of target inhibition and potentially of 89 
tumour response would be of value in the clinical development of the AKT inhibitor 90 
MK-2206. 91 
 92 
Reprogrammed metabolism is one of the hallmarks of cancer (Hanahan and 93 
Weinberg, 2011; Pavlova and Thompson, 2016). As many oncogenic signalling 94 
pathways that regulate cancer have also been shown to regulate metabolism (Iurlaro et 95 
al, 2014; Tarrado-Castellarnau et al, 2016), targeting those signalling pathways with 96 
drugs such as MK-2206 is expected to impact on metabolic intermediates. Assessment 97 
of the metabolic effects of drug treatment using functional imaging modalities, such 98 
as magnetic resonance spectroscopy (MRS) and metabolic PET, to provide an early 99 
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treatment response biomarkers to molecularly targeted drugs is being increasingly 100 
investigated for clinical biomarker discovery (Beloueche-Babari et al, 2010; 101 
Beloueche-Babari et al, 2011; Moestue et al, 2011; Serkova and Eckhardt, 2016; 102 
Workman et al, 2006).  103 
 104 
MRS provides a non-invasive and non-ionizing method of detecting various 105 
tissue metabolites in vitro, ex vivo and in vivo (Gadian, 1995). Numerous studies have 106 
investigated MRS-detectable metabolic biomarkers in response to novel targeted 107 
therapies that are in pre-clinical development or early phase clinical evaluation 108 
including inhibitors of HSP90, MAPK, HDAC, PI3K/AKT/mTOR and related 109 
pathways, reviewed in (Beloueche-Babari et al, 2010; Beloueche-Babari et al, 2011; 110 
Moestue et al, 2011). 111 
 112 
Using MRS, we and others have previously reported alterations in the levels of 113 
choline metabolites and/or lactate in response to different PI3K/mTOR pathway 114 
inhibitors in vitro and in vivo in various cancer models (Al-Saffar et al, 2010; Al-115 
Saffar et al, 2014; Beloueche-Babari et al, 2006; Chaumeil et al, 2012; Esmaeili et al, 116 
2014; Euceda et al, 2017; Koul et al, 2010; Lee et al, 2013; Moestue et al, 2013; Phyu 117 
et al, 2016; Venkatesh et al, 2012). However to the best of our knowledge, metabolic 118 
biomarkers for AKT inhibitors have only been evaluated in vitro and ex vivo in breast 119 
cancer models (Moestue et al, 2013; Phyu et al, 2016; Su et al, 2012), and there are 120 
no previous metabolic biomarker studies in vivo in tumour xenografts. In one study 121 
(Su et al, 2012), treatment of MCF-7 and MDA-MB-231 breast cancer cells with the 122 
alkylphospholipid AKT inhibitor perifosine resulted in decreases in PC and lactate 123 
production. Two studies reported different results using the allosteric AKT inhibitor 124 
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MK-2206, which provides greater specificity, reduced side-effects and less toxicity 125 
compared to alkylphospholipid AKT inhibitors (Nitulescu et al, 2016). A decrease in 126 
PC levels was observed in vitro in MDA-MB-468 breast cancer cells (Phyu et al, 127 
2016), while an increase in PC and a decrease in lactate levels were detected ex vivo 128 
in basal-like breast cancer tumours following treatment with MK-2206 (Moestue et al, 129 
2013). 130 
 131 
In view of the inconsistent published findings with the allosteric AKT inhibitor 132 
MK-2206, and the lack of in vivo studies in cancer models, we set out to assess the 133 
metabolic changes in response to MK-2206 both in vitro and in vivo in subcutaneous 134 
and orthotopic animal xenograft models of colon and prostate cancer, with potential to 135 
develop these metabolic changes as non-invasive biomarkers for monitoring response 136 
in clinical trials. 137 
 138 
Our results show that treatment with the AKT inhibitor MK-2206 results in 139 
metabolic changes detectable with MRS. Importantly, a decrease in the total choline 140 
(tCho)/water ratio was observed in the more clinically relevant orthotopic model of 141 
the PC3 prostate cancer and therefore may provide a potential non-invasive biomarker 142 
for monitoring response to MK-2206 during clinical trials. 143 
144 
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Materials and Methods 145 
Cell culture and treatment. The human PTEN null PC3 prostate adenocarcinoma 146 
and PIK3CA mutant HT29 colorectal carcinoma cell lines (American Type Culture 147 
Collection) were cultured in DMEM (Life Technologies) supplemented with 10% 148 
fetal calf serum (PAA labs Ltd), 100 U/mL penicillin, and 100 μg/mL streptomycin 149 
(Life Technologies) at 37°C in 5% CO2. Cell viability was routinely >90%, as judged 150 
by trypan blue exclusion. All cell lines were shown to be mycoplasma free using a 151 
PCR-based assay (Surrey Diagnostics Ltd) and were authenticated in our laboratory 152 
by short tandem repeat (STR) profiling. 153 
 154 
Both cell lines were treated with the orally active, highly selective non-ATP 155 
competitive allosteric AKT inhibitor MK-2206 (Merck & Co., Inc.). GI50 values 156 
(concentrations causing 50% inhibition of proliferation for tumour cells) were 157 
determined using the sulforhodamine B assay following 96 h continuous exposure to 158 
compounds (Raynaud et al, 2007). At the required time points, cells underwent 159 
trypsinization and trypan blue exclusion assay (Al-Saffar et al, 2014). The effect of 160 
treatment on cell number was monitored by counting the number of viable attached 161 
cells in a treated flask and comparing that number with the number of attached cells in 162 
a control flask. 163 
 164 
Flow cytometry. Cell cycle analysis was performed as previously described (Al-165 
Saffar et al, 2014). 166 
 167 
Immunoblotting. Western blotting was performed as previously described (Al-Saffar 168 
et al, 2014). Western blots were probed for pAKT (Ser473; 4060), AKT (9272), 169 
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pRPS6 (Ser240/244; 2215), RPS6 (2217), HK2 (2106), PARP (9542), LDHA (3582), 170 
β-Actin (4967), all from Cell Signaling Technology, and CHKA (HPA0241153) from 171 
Sigma. Blots were revealed with peroxidase-conjugated secondary anti-rabbit (GE 172 
Healthcare NA9340) or anti-mouse (DAKO P0260) antibodies followed by ECL 173 
chemiluminescence solution (Amersham Biosciences). 174 
 175 
In vitro 1H- and 31P-MRS of cell extracts. The same number of cells per flask were 176 
seeded at the beginning of the experiment then at the selected time points; cells were 177 
pooled from the number of flasks required to achieve an average cell number of 3x107 178 
cells, which differed depending on the expected effect of treatments on cell number. 179 
To obtain an MR spectrum, cells were extracted from cultured cells using the dual 180 
phase extraction method, as previously described (Al-Saffar et al, 2014; Tyagi et al, 181 
1996). Briefly, cells were rinsed with ice-cold saline and fixed with 10 mL of ice-cold 182 
methanol. Cells were then scraped off the surface of the culture flask and collected 183 
into tubes. Ice-cold chloroform (10 mL) was then added to each tube followed by an 184 
equal volume of ice-cold deionized water. Following phase separation, the solvent in 185 
the upper methanol/water phase was removed by lyophilisation. Prior to acquisition of 186 
the MRS spectra, the water-soluble metabolites were resuspended in deuterium oxide 187 
(D2O) for 1H-MRS or D2O with 10 mM EDTA (pH 8.2) for 31P-MRS. For 188 
extracellular metabolite analysis, 500 μL of cell growth medium was mixed with 100 189 
μL of D2O containing sodium 3-trimethylsilyl-2,2,3,3-tetradeuteropropionate as an 190 
internal reference (TSP; 2.7 mM).  1H-MRS and 1H-decoupled 31P-MRS spectra were 191 
acquired at 25°C on a 500 MHz Bruker spectrometer (Bruker Biospin, Coventry, UK) 192 
using a 90-degree flip angle, a 1 s relaxation delay, spectral width of 12 ppm, 64 K 193 
data points, and HDO resonance suppression by presaturation for 1H-MRS and a 30° 194 
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flip angle, a 1 s relaxation delay, spectral width of 100 ppm, and 32 K data points for 195 
31P. Metabolite contents were determined by integration and normalised relative to the 196 
peak integral of an internal reference [TSP (4.8 mM) for 1H-MRS, and 197 
methylenediphosphonic acid (MDPA; 2 mM) for 31P-MRS] and corrected for signal 198 
intensity saturation (31P-MRS) and the number of cells extracted per sample. 199 
 200 
In vivo tumour propagation. All animal experiments were performed in accordance 201 
with local and national ethical review panel, the UK Home Office Animals (Scientific 202 
Procedures) Act 1986 and the United Kingdom Coordinating Committee on Cancer 203 
Research Guidelines for the Welfare of Animals in Experimental Neoplasia 204 
(Workman et al, 2010). 205 
 206 
Subcutaneous HT29 and PC3 tumour xenografts. Male NCr nude mice were 207 
injected subcutaneously in the flank with 5x106 HT29 (human colon) or PC3 (human 208 
prostate) carcinoma cells. Tumour volume was calculated by measuring the length, 209 
width, and depth using calipers and the ellipsoid formula L x W x D x (π/6). Once the 210 
tumours reached ~400 mm3, the animals were divided to two groups. One group was 211 
treated with 2 doses of 120 mg/kg of MK-2206 on alternate days (Day 1 and 3) via 212 
p.o. and the other group with vehicle alone (10% DMSO in saline).   213 
 214 
Orthotopic PC3 tumour xenografts. PC3 cells (5 x 105) were inoculated in the 215 
ventral prostate gland of nude mice. Once the tumours were palpable, animals were 216 
treated with 2 doses of 120 mg/kg of MK-2206 on alternate days (Day 1 and 3) via 217 
p.o. or vehicle alone (10% DMSO in saline). 218 
 219 
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In vivo MRS of HT29 and PC3 tumours. Mice were anesthetised with a single 220 
intraperitoneal injection of a fentanyl citrate (0.315 mg/mL) plus fluanisone [10 221 
mg/mL (Hypnorm; Janssen Pharmaceutical Ltd., High Wycombe, UK)], midazolam 222 
[5 mg/mL (Hypnovel; Roche, Welwyn Garden City, UK)], and sterile water (1:1:2) at 223 
a dose of 9 mL/kg. They were placed in the bore of a 7 Tesla Bruker MR System 224 
spectrometer (Bruker Biospin, Coventry, United Kingdom) with HT29 and PC3 225 
tumours positioned in the centre of a 15 mm two-turn 1H/31P surface coil. In vivo 226 
localised PRESS 1H-MRS of the tumours was carried out at 37°C on Day 0 (before 227 
treatment) and the last day of treatment (Day 3). 4 mm x 4 mm x4 mm voxels were 228 
selected from fast spin-echo images and shimmed using a localised sequence. The 229 
localised PRESS with water suppression was used to detect choline with a repetition 230 
time of 4 s, echo times 136 ms and 64 transients. 4 transients were used to acquire the 231 
unsuppressed water spectra with the same acquisition parameters as above. Image-232 
selected in vivo spectroscopy (ISIS) 31P-MR spectra were also obtained in 233 
subcutaneous PC3 tumours with a repetition time of 2 s and 64 transients. After the 234 
final MRS scan, tumours were excised and stored at for subsequent ex vivo 1H- and 235 
31P-MRS, MSD® assays or immunohistochemical analysis. 236 
 237 
1H- and 31P-MR spectra were analysed using the JMRUI programme to pre-process, 238 
fit and quantify peak areas of the observed metabolites. Choline levels are expressed 239 
as a ratio relative to the water (tCho/water) signal following corrections for the 240 
number of averages and receiver gains, as these two parameters were different for the 241 
acquisitions of water and choline spectra. Phosphomonoesters (PMEs) were expressed 242 
as ratios relative to total phosphorus (PMEs/total P) signals. 243 
 244 
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Meso Scale Discovery (MSD®) assay. Tumour pharmacodynamic biomarkers for 245 
MK-2206 were assessed by a MSD® multispot electrochemiluminescence 246 
immunoassay system to detect pP70S6K (Thr421/Ser424), total P70S6K, pAKT 247 
(Ser473), pAKT (Thr308), total AKT, pRPS6 (Ser235/236), pRPS6 (Ser240/244) and 248 
total RPS6 in 10 mg tumour lysate of vehicle and MK-2206 treated tumours 249 
according to the manufacturer’s instructions (Meso Scale Discovery, Gaithersburg, 250 
USA). 251 
 252 
Ex vivo MRS of tumour extracts. 100- 200 mg of the freeze-clamped tumours were 253 
finely grinded in liquid nitrogen and extracted using ice-cold methanol, water and 254 
chloroform (1:1:1). The aqueous phase was separated, freeze-dried and reconstituted 255 
in 650 µl D2O. 50 µL of 44 mM TSP in D2O was added to the samples for 1H 256 
chemical shift calibration and quantification. The samples were then placed in 5 mm 257 
NMR tubes and sample pH was adjusted to 7 using perchloric acid or potassium 258 
hydroxide. 1H-MRS of the tumour extracts was performed on a Bruker 500 MHz 259 
nuclear magnetic resonance system (Bruker Biospin, Coventry, United Kingdom) and 260 
spectra were acquired using a pulse and collect NMR sequence with presaturation for 261 
water suppression; 7500 Hz spectral width, 32 K time domain points, 2.7 s relaxation 262 
delay and 256 scans at 298 K. After 1H-MRS, 50 μL of 60 mM EDTA was added to 263 
each sample for chelation of metal ions and 25 μL of 10 mM MDPA was added to the 264 
samples for 31P chemical shift calibration and quantitation. The pH was again adjusted 265 
to 7 and 31P-MRS was performed with 12000 Hz spectral width, 32K time domain 266 
points, 5 s relaxation delay and 3000 scans at 298 K (Chung, 2017).  267 
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MR spectra were analysed using the Bruker Topspin-3.2 software package (Bruker 268 
Biospin, Coventry, UK). Spectra were processed by using exponential multiplication 269 
with a line broadening of 0.3 Hz and 3 Hz for 1H- and 31P-MR spectra, respectively, 270 
then followed by Fourier transform, zero- and first-order phase correction, baseline 271 
correction and spectral peak integration integration. Spectral assignments were based 272 
on literature values (Chung, 2017; Sitter et al, 2002). Water-soluble metabolites 273 
measured by 1H and 31P-MRS were quantified relative to TSP or MDPA, respectively, 274 
and standardised to tumour weight (Chung, 2017). 275 
 276 
Immunohistochemistry. Tumour xenografts were fixed in 10% formaldehyde and 277 
routinely processed for paraffin embedding. For histological evaluation, 5 μm-thick 278 
paraffin wax sections were cut and stained with haematoxylin and eosin (H&E). 279 
Expression of caspase-3 (apoptotic marker), CD31 (micro-vessel density) and Ki67 280 
(proliferation marker) were determined by immunohistochemistry, using the 281 
streptavidin-biotin peroxidase technique. Briefly, sections of 5 μm were 282 
deparaffinised in xylene and rehydrated through graded ethanol concentrations up to 283 
distilled water for 30 min. Antigen retrieval was performed by microwaving the 284 
sections in 10 mM sodium citrate buffer pH 6 at 10 min intervals for a total of 20 min 285 
and cooling for 1 h at room temperature (RT). Endogenous peroxidase activity was 286 
blocked by incubating the sections in a solution of 3% hydrogen peroxide for 20 min 287 
at RT. After washing in PBS (phosphate buffer saline), sections were incubated with 288 
the primary polyclonal rabbit anti-human caspase-3 (1:50, Abcam ab2302), 289 
monoclonal rabbit anti-human CD31 (1:50, Millipore 04-1074) mouse monoclonal 290 
anti-human Ki67 (1:75, DAKO M7240) antibodies, overnight at 4°C. The sections 291 
were washed with PBS and incubated with a biotinylated secondary antibody for 45 292 
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min, followed by an incubation with streptavidin-biotin horseradish peroxidase 293 
complex (DAKO) for another 45 min, at RT. Staining was carried out using a solution 294 
3,3’-diaminobenzidine (DAB-Sigma), and lightly counterstained with Harris 295 
haematoxylin. 296 
 297 
Evaluation of staining. Sections known to express high levels of caspase-3 298 
(pancreas), CD31 (liver) and Ki67 (tonsil) were included as positive controls, while 299 
negative control slides were incubated with PBS. Caspase-3 and Ki67 immuno-300 
stained slides were assessed by light microscopy and scored with ImageJ (1.50i). A 301 
semi-quantitative method was used to score the microvessels stained with CD31 302 
(Bosari et al, 1992). Three fields showing the highest number of microvessels were 303 
selected using light microscopy and the number of micovessels in these fields were 304 
then manually counted and averaged. Each section was scored by 2 independent 305 
observers at x200 magnification. 306 
 307 
Statistical analysis. Data are presented as the mean ± SD (in vitro) or mean ± SEM 308 
(in vivo and ex vivo) and n ≥ 3. Statistical significance of differences was determined 309 




In vitro investigation of molecular and metabolic effects of treatment with MK-313 
2206 in PC3 human prostate cancer cells. The PTEN null human prostate cell line 314 
PC3 was treated with MK-2206 for 6, 12 and 24 h at a pharmacologically active 315 
concentration corresponding to 5xGI50 (GI50 = 5 μM). Inhibition of the AKT pathway 316 
was evident at all time points as indicated by decreased phosphorylation of AKT 317 
(Ser473) and RPS6 (Ser240/244) in treated cells compared to their controls (Figure 318 
1A). Treatment with MK-2206 also induced apoptosis which was evident at 12 and 24 319 
h following treatment as indicated by PARP cleavage detected by immunoblotting 320 
(Fig 1A). Inhibition of cell growth (down to 66 ± 10%, P = 0.0001) and a G1 cell 321 
cycle arrest was only detectable at 24 h post treatment (Figure 1B). 322 
 323 
31P-and 1H-MRS of aqueous extracts from PC3 cells treated in vitro with the 324 
AKT inhibitor MK-2206 (5xGI50) was used to identify potential biomarkers of AKT 325 
pathway inhibition compared to controls (Figure 1C). Analysis of metabolites 326 
detected with 31P-MRS showed a significant decrease (P ≤ 0.02) in the levels of 327 
phosphoethanolamine (PE), phosphocholine (PC) and NTP which was evident at 6 h 328 
and was maintained at 24 h (Table 1). Levels of glycerophosphoethanolamine (GPE) 329 
and glycerophosphocholine (GPC) were reduced for up to 12 h (P ≤ 0.001) but then a 330 
significant increase (P ≤ 0.01) was observed at 24 h (Table 1). A significant decrease 331 
(P ≤ 0.04) in the levels of phosphocreatine (PCr) was also detected at 12 h and was 332 
maintained at 24 h following treatment with MK-2206. 1H-MRS confirmed changes 333 
in PC and GPC detected with 31P-MRS together resulted in a significant decrease (P ≤ 334 
0.04) in tCho levels (Figure 1D). Furthermore, significant decreases (P ≤ 0.05) in 335 
lactate, alanine, glutamine, glutathione, creatine (Cr) and PCr levels were detected 336 
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over the time course of treatment (Figure 1E). A significant (P ≤ 0.05) decrease in 337 
glutamate and increase in glucose were also found following 24 h of MK-2206 338 
treatment (Figure 1E). We also assessed the metabolic effects of MK-2206 at a lower 339 
concentration equivalent to 3xGI50 for 24 h. This resulted in inhibition of AKT 340 
signalling and cellular growth (down to 84 ± 8%, P = 0.008) as well as a G1 cell cycle 341 
arrest compared to controls, but did not induce apoptosis as detemined by cleaved 342 
PARP (Supplementary Figure S1A). 31P-MRS showed similar changes in PC, PE, PCr 343 
and NTP to those observed with MK-2206 at 5xGI50, but levels of GPE and GPC 344 
were not affected (Table 1). Similarly, decreases in PC, tCho, lactate, alanine, 345 
glutathione, Cr and PCr were detected using 1H-MRS, while glutamate, glutamine and 346 
glucose levels remained unchanged relative to controls (Supplementary Figure S1B 347 
and C). 348 
 349 
In vitro investigation of molecular and metabolic effects of treatment with MK-350 
2206 in HT29 human colon cancer cells. To test for the generality of the MRS-351 
detected data, we also treated PIK3CA mutant HT29 colorectal carcinoma cells with 352 
MK-2206 at 5xGI50 (GI50 = 0.4 μM) for 24 h. Similar to PC3 prostate cells, treatment 353 
with MK-2206 resulted in inhibition of AKT signalling and a G1 cell cycle arrest but 354 
no effects on cell number nor apoptosis were detected relative to controls 355 
(Supplementary Figure S2A and B). Representative 31P- and 1H-MR spectra are 356 
shown in Supplementary Figure S2C. As in PC3 cells, 31P-MRS analysis showed 357 
significant decreases (P ≤ 0.04) in PE, PC, PCr and NTP and increases in GPE and 358 
GPC in spectra from MK-2206 treated cells compared to their controls (Table 1). 1H-359 
MRS confirmed changes in PC, GPC and further showed a reduction in tCho 360 
(Supplementary Figure S2D). Consistent with PC3 cells, significant decreases (P ≤ 361 
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0.04) in lactate, alanine, glutamate, glutamine, glutathione, Cr and PCr were also 362 
observed in HT29 cells following MK-2206 treatment (Supplementary Figure S2E). 363 
In contrast to PC3 cells, treatment with MK-2206 reduced glucose levels in HT29 364 
cells (P < 0.02; Supplementary Figure S2E). 365 
 366 
Assessment of mechanisms underlying the in vitro MRS detected metabolic 367 
changes following treatment with MK-2206. We have used immunoblotting to 368 
identify the effects of AKT inhibition with MK-2206 on enzymes involved in choline 369 
and glucose metabolism. A decrease in choline kinase alpha (CHKA) expression 370 
levels compared to control cells was observed over the time course of treatment with 371 
MK-2206 in PC3 and following 24 h treatment with MK-2206 in HT29 cells 372 
(Supplementary Figure S3A and B). For the glycolytic metabolic changes, reductions 373 
in the protein expression levels of the glycolytic enzymes including hexokinase II 374 
(HK2) and lactate dehydrogenase alpha (LDHA) were detected in both cell lines 375 
following treatment with MK-2206 (Supplementary Figure S3A and B). 376 
 377 
Next, in order to determine whether the changes in intracellular metabolites 378 
could be due to alterations in metabolic flux, we used 1H-MRS to measure levels of 379 
metabolites in the growth media of control and treated cells. In the PC3 cells 380 
(Supplementary Figure S4A), treatment with MK-2206 (5xGI50) caused no significant 381 
changes in external metabolites at 6 h compared to controls. However, significant 382 
increases (P < 0.05) in the levels of alanine, glutamine and choline were observed at 383 
12 h following treatment. High levels of all metabolites were detected in growth 384 
media of 24 h treated cells compared to controls resulting from the release of 385 
metabolites from fragmented apoptotic cells. In contrast, 24 h treatment with MK-386 
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2206 at 3xGI50 only caused a significant increase (P = 0.01) in the level of choline 387 
compared to controls. Increases in the levels of metabolites present in the growth 388 
media from HT29 cells treated with MK-2206 (5xGI50) were detected but did not 389 
reach significance relative to controls (Supplementary Figure S4B).  390 
 391 
In vivo investigation of molecular and metabolic effects of treatment with MK-392 
2206 in subcutaneous HT29 colon xenografts. Significant tumour growth inhibition 393 
was observed in HT29 xenografts after 2 doses (Day 1 and 3) of MK-2206 (120 394 
mg/kg per dose) when compared with vehicle-treated controls (Figure 2A). AKT 395 
inhibition was confirmed by reductions in the phosphorylation of P70S6K, RPS6 396 
(Ser235/236), AKT (Ser473) and AKT (Thr308; Supplementary Figure S5). In vivo 397 
1H-MRS showed a significant decrease (P = 0.04) in the ratio of tCho/water signal in 398 
HT29 xenografts after MK-2206 treatment (Table 2). The in vivo change in 399 
tCho/water was confirmed by lower PC, GPC and GPE levels in ex vivo 31P-MRS 400 
analysis of MK-2206 treated tumour extracts when compared with vehicle controls 401 
(Table 2). Lower levels of glutamine, glutamate, aspartate, glycine, glutathione and Cr 402 
were also seen in MK-2206 treated tumours when compared with controls (Table 2). 403 
Phosphocreatine, ATP+ADP, NTP [0.68 ± 0.07 (control) versus 0.48 ± 0.03 (MK-404 
2206) µmol/g wet weight; P = 0.015] and NDP [0.49 ± 0.02 (control) versus 0.30 ± 405 
0.02 (MK-2206) µmol/g wet weight; P = 0.0004] levels were also found to reduce in 406 
the MK-2206 treated group (Table 2). No change in glucose and lactate levels, 407 
microvessel density, necrosis, proliferation or apoptosis was found in MK-2206 408 




In vivo investigation of molecular and metabolic effects of treatment with MK-412 
2206 in subcutaneous PC3 prostate tumour xenografts. Similar to MK-2206 413 
treated HT29 xenografts, significant tumour growth inhibition was also observed in 414 
PC3 xenografts after 2 doses (Day 1 and 3) of MK-2206 (120 mg/kg per dose) when 415 
compared with vehicle-treated controls (Figure 2B) and AKT inhibition was 416 
confirmed by the reductions in the phosphorylation of P70S6K, RPS6 (Ser235/236), 417 
AKT (Ser473) and AKT (Thr308) (Supplementary Figure S6). In vivo 1H-MRS did 418 
not show a change in the ratio of tCho/water signal in either control or MK-2206 419 
treated PC3 xenografts (Table 3). However, a significant increase (P = 0.02) in the 420 
ratio of PMEs/total P signal was found in MK-2206 treated PC3 xenografts by in vivo 421 
31P-MRS (Table 3), with this in vivo change attributable to a significant increase (P = 422 
0.03) in PE measured by 31P-MRS of MK-2206 treated PC3 tumour extracts (Table 423 
3). Significant decreases (P ≤ 0.04) in GPC, GPE and lactate and increase in 424 
glutamine were also found in MK-2206 treated PC3 tumour extracts when compared 425 
with vehicle controls (Table 3). No change in tumour bioenergetics was observed in 426 
this tumour model following MK-2206 treatment. Immunohistochemical analysis 427 
(Figure 2C) on the tumour samples showed significantly decreased microvessel 428 
density (CD31) in MK-2206 treated tumours (9 ± 2 stained blood vessels average 429 
over 3 fields) when compared to vehicle-controls (14 ± 2; P = 0.05). Using 430 
immunohistochemistry, no change in necrosis, proliferation or apoptosis was found in 431 
MK-2206 treated tumours when compared to controls (Figure 2C). 432 
 433 
In vivo investigation of molecular and metabolic effects of treatment with MK-434 
2206 in orthotopic PC3 prostate xenografts. Next we wanted to examine the 435 
metabolic response to MK-2206 in a more clinically relevant in vivo model. 436 
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Orthotopic PC3 tumours were propagated, treated with MK-2206 (2 doses of 120 437 
mg/kg on Day 1 and 3) and studied by 1H-MRS. AKT inhibition was confirmed by 438 
the reductions in phosphorylated RPS6 (Ser240/244), AKT (Ser473) and AKT 439 
(Thr308; Supplementary Figure S7). In vivo 1H-MRS showed that the tCho/water 440 
ratio was significantly reduced (P = 0.02) in orthotopic PC3 tumours after MK-2206 441 
treatment, with this reduction attributable to a significant decrease (P = 0.003) in PC 442 
as measured ex vivo by 31P-MRS analysis of the tumour extracts (Table 4). Significant 443 
decreases (P ≤ 0.03) in alanine and increases in glucose were also found in MK-2206 444 
treated tumours (Table 4). No changes in tumour bioenergetics, glutamine or 445 
glutathione metabolism were observed in this tumour model following MK-2206 446 
treatment. No change in microvessel density, necrosis, proliferation or apoptosis was 447 




AKT is a central component of the PI3K signalling pathway, influencing 451 
multiple processes that are directly involved in tumorigenesis. Targeting AKT is 452 
therefore a highly attractive anti-cancer strategy and several AKT inhibitors are 453 
currently in different phases of clinical trials (Brown and Banerji, 2017; Khan et al, 454 
2013; Nitulescu et al, 2016). As with most cancer targeted therapy, AKT inhibitors 455 
were shown to cause anti-proliferative, rather than anti-tumour activity, with stable 456 
disease identified as the best overall response (Ahn et al, 2015; Yap et al, 2011; Yap 457 
et al, 2014). Therefore, the use of conventional, anatomically based end-points such 458 
as RECIST is inadequate (Serkova and Eckhardt, 2016; Teng et al, 2013). AKT also 459 
plays a pivotal role in the metabolic reprogramming of cancer, providing a rationale 460 
for the use of non-invasive functional imaging techniques (such as MRS or PET) as 461 
alternative methods to monitor response to this targeted therapy (Beloueche-Babari et 462 
al, 2010; Beloueche-Babari et al, 2011; Moestue et al, 2011; Serkova and Eckhardt, 463 
2016; Workman et al, 2006). 464 
 465 
We used MRS both in vitro and in vivo to identify whether inhibition of AKT 466 
signalling using the allosteric pan-AKT inhibitor MK-2206 would result in metabolic 467 
changes that can potentially be used to monitor response to AKT inhibition in clinical 468 
trials. We performed our investigation using the human PIK3CA mutant colorectal 469 
carcinoma HT29 and PTEN null prostate carcinoma PC3 cancer models as AKT 470 
signalling is involved in the tumorigenesis of colorectal and prostate cancers and AKT 471 
inhibitors are in clinical evaluation for both cancer types (Agarwal et al, 2013; Toren 472 
and Zoubeidi, 2014; Yap et al, 2016).  473 
 474 
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MK-2206 consistently resulted in the reduction of AKT and its downstream, 475 
mTOR, signalling pathways in PC3 and HT29 cells and tumours confirming the 476 
mechanism of action. 477 
 478 
Treatment of PC3 cells with MK-2206 resulted in decreases in PE, PC, tCho, 479 
lactate, alanine, glutamine, glutathione, Cr, PCr and NTP levels from 6 h post-480 
treatment onwards which was associated with AKT/mTOR pathway inhibition, but 481 
was much earlier than the G1 arrest, induction of apoptosis and the decrease in 482 
proliferation which were only evident at 24 h following treatment with MK-2206. 483 
This indicates that our detected metabolic changes are related to the inhibition of 484 
AKT/mTOR signalling rather than to the anti-proliferative effects of the treatment. In 485 
support of previous reports by ourselves and others using PI3K/mTOR/AKT 486 
inhibitors (Al-Saffar et al, 2010; Al-Saffar et al, 2014; Chaumeil et al, 2012; Su et al, 487 
2012; Venkatesh et al, 2012), the decrease in PC levels following MK-2206 treatment 488 
was associated with a decrease in the protein levels of CHKA, the enzyme responsible 489 
for choline phosphorylation to form PC. A decrease in the protein expression levels of 490 
the glycolytic enzymes HK2 and LDHA were also observed following AKT 491 
inhibition, suggesting mechanisms for the depletion of lactate. Higher levels of 492 
choline were also found in the tissue culture media of cells treated with MK-2206 493 
compared to controls indicating inhibition of uptake as another mechanism for the 494 
decrease in intracellular levels of PC. Furthermore, decreased intracellular and 495 
increased extracellular levels of alanine indicate the conversion of pyruvate into 496 
alanine instead of lactate as a result of inhibition of LDHA and increased eflux of 497 
alanine following treatment with MK-2206. A decrease in the intracellular and 498 
increase in the extracellular level of glutamine was also detected in treated cells which 499 
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maybe related to decreased uptake of glutamine into the cells following MK-2206 500 
treatment. 501 
 502 
Treatment with MK-2206 also reduced levels of GPE and GPC for up to 12 h 503 
but then an increase was observed at 24 h. The later increase in GPE and GPC might 504 
be linked to the apoptotic effects of MK-2206 observed at this time point which 505 
would lead to membrane breakdown and remodeling (Morse et al, 2007; Zhang et al, 506 
2018). We have previously observed an increase in GPC following treatment with 507 
some PI3K inhibitors but that was cell line dependent and, moreover, was seen only 508 
after longer inhibition periods (≥ 16 h) and when higher concentrations (5xGI50) of 509 
PI3K pathway inhibitors were used (Al-Saffar et al, 2010; Al-Saffar et al, 2014; 510 
Beloueche-Babari et al, 2006). This was further supported by our findings that when 511 
we used MK-2206 at a concentration equivalent to 3xGI50. This concentration did not 512 
cause apoptosis and had no effects on GPC or GPE levels. 513 
 514 
Similar to PC3 cells, metabolic changes including reductions in PE, PC, tCho, 515 
lactate, alanine, glutamate, glutamine, glutathione, Cr and PCr as well as an increase 516 
in GPE and GPC were detected following treatment of HT29 colorectal carcinoma 517 
cells with MK-2206 at 5xGI50 for 24 h. This was associated with inhibition of 518 
AKT/mTOR signalling and a G1 cell cycle arrest. The observed changes in 519 
phospholipid and glucose metabolism are congruent with the previous reports 520 
examining the effect of the AKT inhibitors perifosine and MK-2206 on breast cancer 521 
cells (Phyu et al, 2016; Su et al, 2012), and suggest that choline-containing 522 
metabolites and lactate may serve as non-invasive metabolic biomarkers for 523 
monitoring the effects of AKT inhibitors. 524 
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 525 
Similar phospholipid and glutamine changes to those detected in HT29 cells 526 
were also observed in HT29 xenografts following treatment with MK-2206. These 527 
were associated with a significant tumour growth delay and pathway inhibition when 528 
compared with vehicle-treated controls. In vivo 1H-MRS analysis of the HT29 tumour 529 
xenografts showed a significant decrease in the ratio of tCho/water signal. This was 530 
further confirmed by significantly lower PC, GPC and GPE levels by ex vivo 31P-531 
MRS of MK-2206 treated tumour extracts when compared with vehicle controls, 532 
supporting the in vitro findings and suggesting that membrane turnover is reduced 533 
following MK-2206 treatment. Tumour bioenergetics was also compromised by 534 
treatment with MK-2206 as indicated by the decrease in the levels of PCr, ATP+ADP, 535 
NTP and NDP. Consistent with our in vitro cell data, alterations in glutamine and 536 
glutathione metabolism with decreased glutamine, glutamate, aspartate, glutathione, 537 
glycine and Cr were also found in HT29 tumours following AKT inhibition with MK-538 
2206. No change in glucose metabolism was observed in MK-2206 treated HT29 539 
xenografts. 540 
 541 
Glutamine is one of the key substrates utilised by cancer cells and its 542 
metabolism is important to tumour growth, malignancy, and survival under stress 543 
(Hensley et al, 2013). Glutamine is involved in nucleotide synthesis (Cory and Cory, 544 
2006), and generation of the anti-oxidant glutathione (Shanware et al, 2011). The 545 
decreases in bioenergetic metabolites, such as nucleotides and PCr following MK-546 
2206 treatment are consistent with the observed decreases in glycine, glutamine and 547 
its downstream metabolites, such as glutamate, aspartate and Cr, suggesting that lower 548 
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tumour bioenergetics following treatment maybe a consequence of changes in 549 
glutamine metabolism. 550 
 551 
Our data also indicate that glutathione biosynthesis may be altered following 552 
MK-2206 treatment, as the total glutathione level together with its precursors, 553 
glutamine and glycine, were lower in the MK-2206 treated PC3 and HT29 cells and 554 
tumours. This is consistent with previous reports that glutathione levels are reduced in 555 
MK-2206 treated lung cancer cells (Dai et al, 2013) and that the PI3K/AKT signalling 556 
pathway in PIK3CA mutant and PTEN mutant breast cancer cells stimulates 557 
glutathione biosynthesis, in order to counteract the effect of oxidative stress (Lien et 558 
al, 2016).   559 
 560 
Different changes in PC levels have been previously reported following 561 
treatment with MK-2206 in MDA-MB-468 breast cancer cells (Phyu et al, 2016) 562 
compared to basal like breast cancer tumours (Moestue et al, 2013). This was the case 563 
with MK-2206 treated subcutaneous PC3 xenografts, where in contrast to PC3 cells, 564 
an increase rather than a decrease in the ratio of PMEs/total P signal was observed by 565 
in vivo 31P-MRS, and no significant difference in the tCho/water ratio was detected by 566 
in vivo 1H-MRS pre vs. post MK-2206 treatment. Further investigations using ex vivo 567 
MRS showed an increase in PE and a decrease in GPC and GPE in MK-2206 treated 568 
subcutaneous PC3 tumour extracts when compared with vehicle controls. These 569 
changes in choline and ethanolamine metabolites could explain the lack of change in 570 
the in vivo MRS detected tCho/water signal as it consists of PC, PE, GPC and GPE, 571 
and the increase in PMEs consisting of PC and PE. 572 
 573 
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Differences in phospholipid metabolism between PC3 cells in culture and in 574 
subcutaneous tumours derived from these cells have been previously reported and was 575 
attributed to the influence of the tumour microenvironment on choline and lipid 576 
metabolism (Mori et al, 2016). However, our MRS detected phospholipid changes 577 
observed in the colorectal HT29 subcutaneous tumours are consistent with our in vitro 578 
findings both in HT29 and PC3 cells and also in line with the previously published 579 
MRS changes using the AKT inhibitors perifosine and MK-2206 in breast cancer cells 580 
(Phyu et al, 2016; Su et al, 2012). We also did not observe any differences in the 581 
cellular or molecular effects of MK-2206 in both tumour models. We therefore 582 
questioned whether the difference in the phospholipid biomarker changes in the PC3 583 
subcutaneous tumours was due to the location of the tumour, and whether growing 584 
PC3 tumours orthotopically would result in a different metabolic response to 585 
treatment with the AKT inhibitor MK-2206 compared to PC3 subcutaneous tumours. 586 
Orthotopic tumour models are more clinically relevant compared to subcutaneous 587 
tumours. A previous study showed images in real time, using green fluorescent 588 
protein (GFP) expression, of the very different tumour behaviour at the orthotopic and 589 
subcutaneous sites of human prostate cancer PC3 in athymic nude mice. The 590 
orthotopic tumour described had higher rates of vascularisation, migration, 591 
angiogenesis and metastasis compared to the subcutaneous tumour (Zhang et al, 592 
2016). Indeed, inhibition of AKT signalling with MK-2206 in orthotopic PC3 593 
tumours resulted in a significant reduction in the tCho/water ratio using in vivo 1H-594 
MRS and this was due to a decrease in PC levels as shown in the MRS analysis of the 595 
tumour extracts. Similar to MK-2206 treated PC3 and HT29 cells, orthotopic PC3 596 
tumours treated with MK-2206 also showed reduced alanine and increased glucose, 597 
suggesting an alteration in glucose metabolism. MK-2206 had no effect on tumour 598 
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bioenergetics, glutamine or glutathione metabolism, microvessel density, necrosis, 599 
proliferation or apoptosis. This shows that the difference in metabolic response 600 
between subcutaneous and orthotopic PC3 tumours could reflect the difference in 601 
tumour microenvironment at different tumour sites. 602 
 603 
We have provided further evidence that in vitro inhibition of AKT is associated 604 
with changes in glucose, glutamine and choline metabolism both in prostate and 605 
colorectal cancer cell lines. We also demonstrated that the reduction in choline 606 
metabolites can be detected in vivo both in subcutaneous and the clinically relevant 607 
orthotopic prostate cancer tumours. A Phase I trial study published previously 608 
investigated the utility of 1H-MRS (amongst a number of functional imaging 609 
biomarkers) to monitor patient response to MK-2206 (Yap et al, 2014). Individual but 610 
not cohort 1H-MRS detected changes in tCho/water ratio have been reported. This 611 
was possibly due to insufficient target and pathway modulation as the ultimate 612 
maximum tolerated dose (MTD) was limited by Dose Limiting Toxicities (DLTs) of 613 
rash during dose escalation. The Phase I study also involved a very small population 614 
of patients. The authors suggested that functional imaging studies including total 615 
choline levels should be considered in phase II trials using a higher dose of MK-2206. 616 
Taken together, our MRS-detected choline metabolites may have potential as 617 
non-invasive biomarkers for monitoring response to treatment with AKT inhibitors 618 
during Phase I/II clinical trials in selected cancer types. 619 
620 
  27
Additional Information: 621 
 622 
Ethics approval 623 
All animal experiments were performed in accordance with local and national ethical 624 
review panel, the UK Home Office Animals (Scientific Procedures) Act 1986 and the 625 
United Kingdom Coordinating Committee on Cancer Research Guidelines for the 626 
Welfare of Animals in Experimental Neoplasia (Workman et al. BJC 2010) 627 
 628 
Availability of data and material 629 
All data generated or analysed during this study are included in this published article 630 
and its supplementary information files. 631 
 632 
Conflict of interest.  633 
The authors declare no conflict of interest. 634 
 635 
Funding 636 
This work is funded by Cancer Research UK and EPSRC Cancer Imaging Centre in 637 
association with the MRC and Department of Health (England) grant C1060/A10334 638 
and C1060/A16464 for M.O.L, Y-L.C, N.M.S.A, A.C.W.T.F, R.P., S.P.R, J.K.R.B, 639 
and L.E.J. M.O.L is an Emeritus NIHR Senior Investigator. All authors acknowledge 640 
National Health Service funding to the NIHR Biomedical Research Centre. 641 
 642 
Authors’ contributions 643 
NMSA and Y-LC wrote the manuscript text. NMSA, Y-LC, TAY and MOL 644 
conceived the study. NMSA, Y-LC, HT, LEJ, ACWTF, SG, RP and JKRB designed 645 
  28
and performed experiments. NMSA, Y-LC, ACWTF and SG analysed the data. 646 
NMSA, Y-LC, SPR, SAE and MOL contributed reagents/ materials/analysis tools. All 647 
authors reviewed the manuscript. 648 
 649 
Acknowledgements 650 








Agarwal, E., Brattain, M. G., and Chowdhury, S. (2013). Cell survival and metastasis 657 
regulation by Akt signaling in colorectal cancer. Cell Signal 25, 1711-1719. 658 
Ahn, D. H., Li, J., Wei, L., Doyle, A., Marshall, J. L., Schaaf, L. J., Phelps, M. A., 659 
Villalona-Calero, M. A., and Bekaii-Saab, T. (2015). Results of an abbreviated phase-660 
II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer. 661 
Sci Rep 5, 12122. 662 
Al-Saffar, N. M., Jackson, L. E., Raynaud, F. I., Clarke, P. A., Ramírez de Molina, A., 663 
Lacal, J. C., Workman, P., and Leach, M. O. (2010). The Phosphoinositide 3-Kinase 664 
Inhibitor PI-103 Downregulates Choline Kinase {alpha} Leading to Phosphocholine 665 
and Total Choline Decrease Detected by Magnetic Resonance Spectroscopy. Cancer 666 
Res 70, 5507-5517. 667 
Al-Saffar, N. M., Marshall, L. V., Jackson, L. E., Balarajah, G., Eykyn, T. R., 668 
Agliano, A., Clarke, P. A., Jones, C., Workman, P., Pearson, A. D., and Leach, M. O. 669 
(2014). Lactate and choline metabolites detected in vitro by nuclear magnetic 670 
resonance spectroscopy are potential metabolic biomarkers for PI3K inhibition in 671 
pediatric glioblastoma. PLoS One 9, e103835. 672 
Beloueche-Babari, M., Chung, Y. L., Al-Saffar, N. M., Falck-Miniotis, M., and 673 
Leach, M. O. (2010). Metabolic assessment of the action of targeted cancer 674 
therapeutics using magnetic resonance spectroscopy. BrJCancer 102, 1-7. 675 
Beloueche-Babari, M., Jackson, L. E., Al-Saffar, N. M. S., Eccles, S. A., Raynaud, F. 676 
I., Workman, P., Leach, M. O., and Ronen, S. M. (2006). Identification of magnetic 677 
resonance detectable metabolic changes associated with inhibition of 678 
phosphoinositide 3-kinase signaling in human breast cancer cells. Molecular Cancer 679 
Therapeutics 5, 187-196. 680 
  31
Beloueche-Babari, M., Workman, P., and Leach, M. O. (2011). Exploiting tumor 681 
metabolism for non-invasive imaging of the therapeutic activity of molecularly 682 
targeted anticancer agents. Cell Cycle 10, 2883-2893. 683 
Bosari, S., Lee, A. K., DeLellis, R. A., Wiley, B. D., Heatley, G. J., and Silverman, 684 
M. L. (1992). Microvessel quantitation and prognosis in invasive breast carcinoma. 685 
Hum Pathol 23, 755-761. 686 
Brown, J. S., and Banerji, U. (2017). Maximising the potential of AKT inhibitors as 687 
anti-cancer treatments. Pharmacol Ther 172, 101-115. 688 
Chaumeil, M. M., Ozawa, T., Park, I., Scott, K., James, C. D., Nelson, S. J., and 689 
Ronen, S. M. (2012). Hyperpolarized 13C MR spectroscopic imaging can be used to 690 
monitor Everolimus treatment in vivo in an orthotopic rodent model of glioblastoma. 691 
Neuroimage 59, 193-201. 692 
Chung, Y. L. (2017). Magnetic Resonance Spectroscopy (MRS)-Based Methods for 693 
Examining Cancer Metabolism in Response to Oncogenic Kinase Drug Treatment. 694 
Methods Mol Biol 1636, 393-404. 695 
Cory, J. G., and Cory, A. H. (2006). Critical roles of glutamine as nitrogen donors in 696 
purine and pyrimidine nucleotide synthesis: asparaginase treatment in childhood acute 697 
lymphoblastic leukemia. In Vivo 20, 587-589. 698 
Dai, B., Yoo, S. Y., Bartholomeusz, G., Graham, R. A., Majidi, M., Yan, S., Meng, J., 699 
Ji, L., Coombes, K., Minna, J. D. et al (2013). KEAP1-dependent synthetic lethality 700 
induced by AKT and TXNRD1 inhibitors in lung cancer. Cancer Res 73, 5532-5543. 701 
Esmaeili, M., Bathen, T. F., Engebraten, O., Maelandsmo, G. M., Gribbestad, I. S., 702 
and Moestue, S. A. (2014). Quantitative (31)P HR-MAS MR spectroscopy for 703 
detection of response to PI3K/mTOR inhibition in breast cancer xenografts. Magnetic 704 
  32
resonance in medicine : official journal of the Society of Magnetic Resonance in 705 
Medicine / Society of Magnetic Resonance in Medicine 71, 1973-1981. 706 
Euceda, L. R., Hill, D. K., Stokke, E., Hatem, R., El Botty, R., Bieche, I., Marangoni, 707 
E., Bathen, T. F., and Moestue, S. A. (2017). Metabolic Response to Everolimus in 708 
Patient-Derived Triple-Negative Breast Cancer Xenografts. J Proteome Res 16, 1868-709 
1879. 710 
Gadian, D. G. (1995). The information available from NMR. In NMR and its 711 
applications to living systems,  (New York: Oxford University Press Inc.), pp. 29-64. 712 
Hanahan, D., and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. 713 
Cell 144, 646-674. 714 
Hensley, C. T., Wasti, A. T., and DeBerardinis, R. J. (2013). Glutamine and cancer: 715 
cell biology, physiology, and clinical opportunities. J Clin Invest 123, 3678-3684. 716 
Iurlaro, R., Leon-Annicchiarico, C. L., and Munoz-Pinedo, C. (2014). Regulation of 717 
cancer metabolism by oncogenes and tumor suppressors. Methods Enzymol 542, 59-718 
80. 719 
Khan, K. H., Yap, T. A., Yan, L., and Cunningham, D. (2013). Targeting the PI3K-720 
AKT-mTOR signaling network in cancer. Chin J Cancer 32, 253-265. 721 
Koul, D., Shen, R., Kim, Y. W., Kondo, Y., Lu, Y., Bankson, J., Ronen, S. M., 722 
Kirkpatrick, D. L., Powis, G., and Yung, W. K. (2010). Cellular and in vivo activity 723 
of a novel PI3K inhibitor, PX-866, against human glioblastoma. NeuroOncol. 724 
Lee, S. C., Marzec, M., Liu, X., Wehrli, S., Kantekure, K., Ragunath, P. N., Nelson, 725 
D. S., Delikatny, E. J., Glickson, J. D., and Wasik, M. A. (2013). Decreased lactate 726 
concentration and glycolytic enzyme expression reflect inhibition of mTOR signal 727 
transduction pathway in B-cell lymphoma. NMR Biomed 26, 106-114. 728 
  33
Lien, E. C., Lyssiotis, C. A., Juvekar, A., Hu, H., Asara, J. M., Cantley, L. C., and 729 
Toker, A. (2016). Glutathione biosynthesis is a metabolic vulnerability in PI(3)K/Akt-730 
driven breast cancer. Nat Cell Biol 18, 572-578. 731 
Manning, B. D., and Toker, A. (2017). AKT/PKB Signaling: Navigating the Network. 732 
Cell 169, 381-405. 733 
Moestue, S. A., Dam, C. G., Gorad, S. S., Kristian, A., Bofin, A., Maelandsmo, G. 734 
M., Engebraten, O., Gribbestad, I. S., and Bjorkoy, G. (2013). Metabolic biomarkers 735 
for response to PI3K inhibition in basal-like breast cancer. Breast Cancer Res 15, 736 
R16. 737 
Moestue, S. A., Engebraaten, O., and Gribbestad, I. S. (2011). Metabolic effects of 738 
signal transduction inhibition in cancer assessed by magnetic resonance spectroscopy. 739 
Mol Oncol 5, 224-241. 740 
Mori, N., Wildes, F., Takagi, T., Glunde, K., and Bhujwalla, Z. M. (2016). The 741 
Tumor Microenvironment Modulates Choline and Lipid Metabolism. Front Oncol 6, 742 
262. 743 
Morse, D. L., Galons, J. P., Payne, C. M., Jennings, D. L., Day, S., Xia, G., and 744 
Gillies, R. J. (2007). MRI-measured water mobility increases in response to 745 
chemotherapy via multiple cell-death mechanisms. NMR Biomed 20, 602-614. 746 
Nitulescu, G. M., Margina, D., Juzenas, P., Peng, Q., Olaru, O. T., Saloustros, E., 747 
Fenga, C., Spandidos, D., Libra, M., and Tsatsakis, A. M. (2016). Akt inhibitors in 748 
cancer treatment: The long journey from drug discovery to clinical use (Review). Int J 749 
Oncol 48, 869-885. 750 
Pavlova, N. N., and Thompson, C. B. (2016). The Emerging Hallmarks of Cancer 751 
Metabolism. Cell Metab 23, 27-47. 752 
  34
Phyu, S. M., Tseng, C. C., Fleming, I. N., and Smith, T. A. (2016). Probing the 753 
PI3K/Akt/mTor pathway using (31)P-NMR spectroscopy: routes to glycogen synthase 754 
kinase 3. Sci Rep 6, 36544. 755 
Raynaud, F. I., Eccles, S., Clarke, P. A., Hayes, A., Nutley, B., Alix, S., Henley, A., 756 
Di-Stefano, F., Ahmad, Z., Guillard, S. et al (2007). Pharmacologic characterization 757 
of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Research 67, 758 
5840-5850. 759 
Serkova, N. J., and Eckhardt, S. G. (2016). Metabolic Imaging to Assess Treatment 760 
Response to Cytotoxic and Cytostatic Agents. Front Oncol 6, 152. 761 
Shanware, N. P., Mullen, A. R., DeBerardinis, R. J., and Abraham, R. T. (2011). 762 
Glutamine: pleiotropic roles in tumor growth and stress resistance. J Mol Med (Berl) 763 
89, 229-236. 764 
Sitter, B., Sonnewald, U., Spraul, M., Fjosne, H. E., and Gribbestad, I. S. (2002). 765 
High-resolution magic angle spinning MRS of breast cancer tissue. NMR Biomed 15, 766 
327-337. 767 
Su, J. S., Woods, S. M., and Ronen, S. M. (2012). Metabolic consequences of 768 
treatment with AKT inhibitor perifosine in breast cancer cells. NMR Biomed 25, 379-769 
388. 770 
Tarrado-Castellarnau, M., de Atauri, P., and Cascante, M. (2016). Oncogenic 771 
regulation of tumor metabolic reprogramming. Oncotarget 7, 62726-62753. 772 
Teng, F. F., Meng, X., Sun, X. D., and Yu, J. M. (2013). New strategy for monitoring 773 
targeted therapy: molecular imaging. Int J Nanomedicine 8, 3703-3713. 774 
Toren, P., and Zoubeidi, A. (2014). Targeting the PI3K/Akt pathway in prostate 775 
cancer: challenges and opportunities (review). Int J Oncol 45, 1793-1801. 776 
  35
Tyagi, R. K., Azrad, A., Degani, H., and Salomon, Y. (1996). Simultaneous extraction 777 
of cellular lipids and water-soluble metabolites: Evaluation by NMR spectroscopy. 778 
Magnetic Resonance in Medicine 35, 194-200. 779 
Venkatesh, H. S., Chaumeil, M. M., Ward, C. S., Haas-Kogan, D. A., James, C. D., 780 
and Ronen, S. M. (2012). Reduced phosphocholine and hyperpolarized lactate provide 781 
magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma. 782 
NeuroOncol 14, 315-325. 783 
Workman, P., Aboagye, E. O., Balkwill, F., Balmain, A., Bruder, G., Chaplin, D. J., 784 
Double, J. A., Everitt, J., Farningham, D. A., Glennie, M. J. et al (2010). Guidelines 785 
for the welfare and use of animals in cancer research. Br J Cancer 102, 1555-1577. 786 
Workman, P., Aboagye, E. O., Chung, Y. L., Griffiths, J. R., Hart, R., Leach, M. O., 787 
Maxwell, R. J., McSheehy, P. M., Price, P. M., and Zweit, J. (2006). Minimally 788 
invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing 789 
clinical trials of innovative therapies. Journal Of The National Cancer Institute 98, 790 
580-598. 791 
Yap, T. A., Smith, A. D., Ferraldeschi, R., Al-Lazikani, B., Workman, P., and de 792 
Bono, J. S. (2016). Drug discovery in advanced prostate cancer: translating biology 793 
into therapy. Nat Rev Drug Discov 15, 699-718. 794 
Yap, T. A., Yan, L., Patnaik, A., Fearen, I., Olmos, D., Papadopoulos, K., Baird, R. 795 
D., Delgado, L., Taylor, A., Lupinacci, L. et al (2011). First-in-man clinical trial of 796 
the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin 797 
Oncol 29, 4688-4695. 798 
Yap, T. A., Yan, L., Patnaik, A., Tunariu, N., Biondo, A., Fearen, I., Papadopoulos, 799 
K. P., Olmos, D., Baird, R., Delgado, L. et al (2014). Interrogating two schedules of 800 
the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating 801 
  36
novel pharmacodynamic and functional imaging biomarkers. Clin Cancer Res 20, 802 
5672-5685. 803 
Zhang, Y., Chen, X., Gueydan, C., and Han, J. (2018). Plasma membrane changes 804 
during programmed cell deaths. Cell Res 28, 9-21. 805 
Zhang, Y., Toneri, M., Ma, H., Yang, Z., Bouvet, M., Goto, Y., Seki, N., and 806 
Hoffman, R. M. (2016). Real-Time GFP Intravital Imaging of the Differences in 807 
Cellular and Angiogenic Behavior of Subcutaneous and Orthotopic Nude-Mouse 808 




Figure Legends 812 
Figure 1. Molecular and metabolic changes caused by treatment with MK-2206 813 
in PC3 prostate cancer cells. (A) Representative immunoblots showing changes in 814 
molecular markers demonstrating AKT inhibition and induction of apoptosis as 815 
evidenced by cleaved PARP. β-Actin is used as a loading control. (B) Flow cytometry 816 
analysis histograms showing cell cycle distribution of cells with vehicle treatment 817 
(DMSO, control), or following treatment with MK-2206 (5xGI50) at 24 h post 818 
treatment, P < 0.002 for G1&S phases. (C) Representative in vitro 31P-MR spectra 819 
(left) and expansion of 1H-MR spectra region (1.3-3.3 ppm; right) showing choline–820 
containing metabolites, Cr/PCr, lactate (Lac) and amino acids (Ala = alanine; Glu = 821 
glutamate; Gln = glutamine; GSH = glutathione). A summary of 1H-MRS metabolic 822 
changes caused by MK-2206 treatment (5xGI50, 24 h) of PC3 prostate cancer cells: 823 
(D) Choline-containing metabolites. (E) Amino acids, Cr/PCr and glycolytic 824 
intermediates. Results are expressed as %T/C and presented as mean ± SD, n ≥ 5. 825 
Statistically significant differences from the control *P ≤ 0.05, **P ≤ 0.01; ***P ≤ 826 
0.001. 827 
 828 
Figure 2. Tumour volume and histological changes in subcutaneous tumours 829 
following MK-2206 treatment. Percentage change in HT29 (A) and subcutaneous 830 
PC3 (B) tumour volumes (relative to Day 1) following 2 doses (Day 1 and 3) of 120 831 
mg/kg of MK-2206 on alternate days via p.o. (n = 10) or vehicle alone (10% DMSO 832 
in saline), minimum n = 10. Data are expressed as mean ± SEM, ****P < 0.0001. (C) 833 
Immunohistochemistry of Ki67, caspase-3 and CD31 expressions (brown staining) in 834 
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vehicle-treated control (left column) and MK-2206 treated (right column) 835 
subcutaneous PC3 xenografts (right column). Magnification x 200. 836 
 837 
 
Table 1. Analysis of 31P-MRS-detected metabolic changes following inhibition 
with MK-2206 in: 
 PC3 
 6 h 
(5xGI50) 
P 12 h 
(5xGI50)
P 24 h 
(5xGI50)
P 24 h 
(3xGI50) 
P 
PE 62 ± 16 0.008 47 ± 11 0.001 23 ± 16 0.0001 43 ± 26 0.01 
PC 74 ± 14 0.02 78 ± 11 0.02 69 ± 13 0.001 71 ± 5 0.0004 
GPE 66 ± 34 ns 50 ± 12 0.001 320 ± 104 0.005 153 ± 40 ns 
GPC 32 ± 16 0.001 36 ± 11 0.0003 225 ± 63 0.007 121 ± 27 ns 
PCr 74 ± 28 ns 54 ± 31 0.04 38 ± 24 0.007 46 ± 24 0.01 
NTP 63 ± 17 0.01 56 ± 12 0.002 68 ± 18 0.005 82 ± 11 0.03 
Data are expressed as %T/C and presented as the mean ± SD, n ≥ 4. 
Two-tailed unpaired t test was used to compare results in treated cells to controls 
within the same time-point. 
 
 HT29 
 24 h 
(5xGI50) 
P 
PE 60 ± 9 0.001 
PC 67 ± 6 0.0001 
GPE 132 ± 26 0.04 
GPC 169 ± 31 0.004 
PCr 59 ± 8 0.0001 




Table 2: In vivo and ex vivo 1H- and 31P-MRS metabolic analysis of HT29 
subcutaneous tumours and extracts following MK-2206 treatment. 





Pre- Post- Pre Post 
Corrected tCho/water ratio x 10-3 8.05 ± 1.11 6.25 ± 1.84 9.22 ± 1.42 4.33 ±1.03 
 P = 0.31 *P = 0.04 
*Statistically significant when compared the pre-MK-2206 treatment values with 
post-treatment. Two-tailed paired t test was used and data are expressed as 
mean±sem. 
 
Ex vivo 1H- and 31P-MRS of subcutaneous HT29 tumour extracts 
 Vehicle-Control MK-2206 p 
PE 1.27 ± 0.10 1.28 ± 0.11 0.96 
PC 1.95 ± 0.12 1.60 ± 0.09 0.04* 
GPE 1.21 ± 0.14 0.87 ± 0.07 0.03* 
GPC 2.51 ± 0.13 1.94 ± 0.18 0.04* 
Lactate 5.81 ± 0.58 7.78 ± 0.92 0.10 
Alanine 1.49 ± 0.15 1.27 ± 0.08 0.25 
Glucose 0.79 ± 0.10 0.70 ± 0.13 0.61 
Glutamine 1.01 ± 0.06 0.72 ± 0.02 0.002* 
Glutamate 2.67 ± 0.23 1.56 ± 0.30 0.02* 
Aspartate 0.35 ± 0.04 0.20 ± 0.05 0.05* 
Glycine 0.67 ± 0.11 0.37 ± 0.06 0.04* 
Glutathione 1.30 ± 0.11 0.85 ± 0.08 0.007* 
Creatine 3.82 ± 0.21 2.87 ± 0.19 0.008* 
Phosphocreatine 1.20 ± 0.08 0.74 ± 0.08 0.004* 
ATP+ADP 1.38 ± 0.08 1.07 ± 0.07 0.02* 
Data are expressed as µmol/g wet weight and presented as the mean±sem, n ≥ 5 in 
each group. Two-tailed unpaired t test was used to compare MK2206-treated tumour 




Table 3: In vivo and ex vivo 1H- and 31P-MRS metabolic analysis of subcutaneous 
PC3 tumours and extracts following MK-2206 treatment. 
In vivo 1H- and 31P-MRS of subcutaneous PC3 tumours 
 Vehicle-Control MK-2206 
Pre- Post- Pre- Post- 
Corrected tCho/water ratio x10-3 
(n = 4 in each group) 
3.63 ± 0.38 3.80 ± 0.64 3.26 ± 0.26 3.61 ± 0.17  
 P = 0.66 P = 0.31 
PME/total P ratio 
(n = 5 in each group) 
0.11 ± 0.01 0.12 ± 0.01 0.14 ± 0.01 0.17 ± 0.02 
 P = 0.50 *P = 0.02 
*Statistically significant when compared the pre-MK-2206 treatment values with 
post-treatment. Two-tailed paired t test was used and data are expressed as 
mean±sem. PME – phosphomonoesters, total P – total phorphorus signal. 
 
Ex vivo 1H- and 31P-MRS of subcutaneous PC3 tumour extracts 
 Vehicle-Control MK-2206 
 
p 
PE 1.03 ± 0.10 1.45 ± 0.13 0.03* 
PC 1.53 ± 0.05 1.60 ± 0.20 0.75 
GPE 0.44 ± 0.03 0.28 ± 0.04 0.02* 
GPC 1.54 ± 0.14 0.94 ± 0.19 0.04* 
Lactate 9.34 ± 0.85 7.14 ± 0.44 0.04* 
Alanine 1.39 ± 0.13 1.49 ± 0.23 0.74 
Glucose 0.45 ± 0.06 0.41 ± 0.03 0.48 
Glutamine 1.20 ± 0.16 2.74 ± 0.48 0.02* 
Glutamate 3.64 ± 0.41 3.02 ± 0.37 0.28 
Glycine 1.21 ± 0.18 1.39 ± 0.16 0.48 
Glutathione 1.53 ± 0.15 1.46 ± 0.12 0.74 
Creatine 1.08 ± 0.09 1.38 ± 0.24 0.32 
Phosphocreatine 0.39 ± 0.05 0.53 ± 0.05 0.08 
ATP+ADP 0.84 ± 0.05 0.89 ± 0.07 0.63 
Data are expressed as µmol/g wet weight and presented as the mean±sem, n ≥ 5 in 
each group. Two-tailed unpaired t test was used to compare MK2206-treated tumour 
extracts with vehicle-treated controls and *P ≤ 0.05 is considered significant.   




Table 4: In vivo and ex vivo 1H- and 31P-MRS metabolic analysis of orthotopic 
PC3 tumours and extracts following MK-2206 treatment. 





Pre- Post- Pre Post 
Corrected tCho/water ratio x10-3 5.11 ± 0.68 4.25 ± 0.47 5.03 ± 0.69 3.92 ± 0.56
 P = 0.36 *P = 0.02 
*Statistically significant when compared the pre-MK-2206 treatment values with 
post-treatment. Two-tailed paired t test was used and data are expressed as 
mean±sem. 
 
Ex vivo 1H- and 31P-MRS of orthotopic PC3 tumour extracts 
 Vehicle-Control MK-2206 P 
PE 1.58 ± 0.18 1.20 ± 0.13 0.14 
PC 1.80 ± 0.06 1.47 ± 0.06 0.003* 
GPE 0.46 ± 0.03 0.45 ± 0.05 0.95 
GPC 1.79 ± 0.35 2.16 ± 0.17 0.40 
Lactate 5.32 ± 0.65 3.96 ± 0.50 0.14 
Alanine 1.09 ± 0.09 0.78 ± 0.07 0.03* 
Glucose 0.33 ± 0.04 0.79 ± 0.15 0.009* 
Glutamine 1.28 ± 0.16 0.97 ± 0.13 0.18 
Glutamate 3.10 ± 0.25 2.50 ± 0.16 0.08 
Aspartate 0.10 ± 0.02 0.08 ± 0.01 0.39 
Glycine 1.06 ± 0.05 1.01 ± 0.14 0.76 
Glutathione 1.59 ± 0.32 1.07 ± 0.09 0.19 
Creatine 1.30 ± 0.16 1.17 ± 0.53 0.26 
Phosphocreatine 0.36 ± 0.10 0.28 ± 0.04 0.50 
ATP+ADP 0.98 ± 0.08 0.89 ± 0.08 0.46 
Data are expressed as µmol/g wet weight and presented as the mean±sem, n ≥ 5 in 
each group. Two-tailed unpaired t test was used to compare MK2206-treated tumour 
extracts with vehicle-treated controls and *P ≤ 0.05 is considered significant. 
 
 


